FDA accepts PaxVax's BLA for cholera vaccine, grants it priority review

Wednesday, December 16, 2015

Just a week after announcing a $105 million investment by Cerberus Capital, PaxVax is inching closer to getting its second vaccine--and potentially the first FDA-approved cholera vaccine--to market. The Redwood City, CA-based company announced Wednesday that the FDA accepted for filing and review the Biologics License Application (BLA) for Vaxchora, its cholera candidate.